Twice-yearly drug eases symptoms in chronic rhinosinusitis with polyps

by

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial investigators, conducted two Phase III clinical trials to evaluate depemokimab, an ultra-long-acting anti-IL-5 biologic drug, for chronic rhinosinusitis with nasal polyps.

Leave A Comment

Your email address will not be published. Required fields are marked *